Search
GC-373
go.drugbank.com/drugs/DB15797ExperimentalIt is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036 … Along with its prodrug, GC-376, GC-373 was recently investigated _in vitro_ in cell culture against SARS-Cov-2 M<sup>pro</sup> [A219036].
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1...
Sulfisoxazole
go.drugbank.com/drugs/DB00263ApprovedVet approvedA short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Synonyms: N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide, 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamideAzlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
Natamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalAmphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
International brands: N-MycinMesmulogene ancovacivec
go.drugbank.com/drugs/DB06584Investigationalwith MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in
Bifenthrin
go.drugbank.com/drugs/DB15056ExperimentalBifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
Atamparib
go.drugbank.com/drugs/DB19028InvestigationalAtamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalXAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma]. … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].